The table contains all the FDA and the EMA‐recommended index substrates and some selected alternatives based on potential advantages in sensitivity, selectivity, and/or relative safety
Management: Limit the dose of rosuvastatin to a maximum of 10 mg/day when used together with elbasvir and
5 CYP3A4 is located in epithelial cells (enterocytes) lining the small intestines and colon, and in the parenchymal cells of the liver (hepatocytes) (Figure 1)
Rosuvastatin is a substrate for certain transporter proteins including the hepatic uptake transporter organic anion-transporting polyprotein 1B1 (OATP1B1) and efflux transporter breast cancer resistance protein (BCRP)
Methods: A comprehensive (PubMed) search was
Blood samples were collected prior to the treatment and The FDA-approved labeling for rosuvastatin, pravastatin, fluvastatin, and pitavastatin does not indicate that a dose adjustment in necessary when coadministered with amiodarone
In addition, it has low potential for drug-drug interactions via CYP enzymes, but as it is actively transported by several different drug transporters, there are DDIs described with
The recommended dose in adults is 40 to 80 mg once daily
4% and 4%, correspondingly
It is mainly suitable for diet management and patients with hyperlipidemia and hypercholesterolemia that cannot be effectively controlled